Pancreatic Enzyme Suppletion in Pancreatic Cancer

Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy

This study will evaluate the effect of immediate pancreatic enzyme suppletion on the physical and mental health status and survival of patients who are diagnosed with pancreatic cancer and are highly likely to develop exocrine pancreatic insufficiency during their disease process.

Weight loss in cancer is caused by primary tumour effects and secondary effects (e.g. side effects of treatment, mechanical and intestinal obstruction). In pancreatic cancer, additional weight loss and malnutrition may be due to the development of exocrine pancreatic insufficiency (EPI). The presence of EPI in pancreatic cancer is frequently overlooked, because the focus of treatment is directed at possible surgery or chemotherapy and its potential side effects. Although studies have proven that pancreatic enzymes may prevent or decrease weight loss, they are seldom being prescribed.

Inclusion Criteria:

• Adenocarcinoma of the pancreas (histologically confirmed)
• Normal exocrine pancreatic function (Fecal Elastase test > 0.2 mg/g)
• Capable and willing to follow instructions given by the physician.

Exclusion Criteria:

• Other causes of fat malabsorption (celiac disease, IBD, and major gastrointestinal surgery).
• < 18 years.